1
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
Condition(s):AMLLast Updated:February 24, 2021Completed
Salvage Chemotherapy: 1187 Clinical Trials, Page 1 of 119
Hide Studies Not Open or Pending
2
A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)
Condition(s):Acute Myeloid Leukemia With FLT3/ITD MutationLast Updated:May 26, 2023Not yet recruiting
3
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
Condition(s):Classical Hodgkin LymphomaLast Updated:July 27, 2023Recruiting
4
A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated
Condition(s):Acute Myeloid Leukemia (AML)Last Updated:November 2, 2021Recruiting
5
Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study
Condition(s):Glioblastoma MultiformeLast Updated:October 20, 2016Unknown status
6
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Condition(s):Leukemia, Acute Myeloid (AML)Last Updated:March 23, 2023Recruiting
7
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Condition(s):Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) MutationLast Updated:August 18, 2023Active, not recruiting
8
OH2 Injection in Melanoma
Condition(s):MelanomaLast Updated:July 13, 2023Recruiting
9
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Condition(s):Leukemia, Acute Myeloid (AML)Last Updated:August 30, 2023Active, not recruiting
10
Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML
Condition(s):Leukemia, Myeloid, AcuteLast Updated:April 28, 2015Unknown status